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The role of bacterial infection in chronic obstructive pulmonary disease (COPD) and how it should be treated has
been an ongoing source of controversy. For many years bacterial infection has not been thought to have an
important effect in the pathology of this condition. Recent advances in diagnostic techniques, particularly the use
16S sequencing has demonstrated that there are a large range of bacteria present in the lower respiratory tract,
both in terms of exacerbations and chronic colonization. A proportion of the bacteria present in the lower
respiratory have also been shown to produce inflammation and hence are likely to be relevant for the
pathogenesis of COPD. The accurate diagnosis of bacterial infection in individual patients remains a major
challenge. The trials that have assessed the effect of antibiotics in COPD have generally been of low quality and
have not been placebo controlled. Recent studies of macrolides for long-term treatment in COPD have found
significantly reduced rates of exacerbations. Major challenges remain in accurately defining the potential role of
bacteria in the inflammatory process and how best to optimize the use of antibiotics without the overuse of this
limited resource. Alternative strategies to treat infection in COPD remain very limited.Review
The role of bacterial infection in COPD and how it
should be treated has been an ongoing source of contro-
versy. The British hypothesis proposed that recurrent
bronchial infections were the reason that some smokers
developed airflow obstruction while others did not [1,2].
The subsequent study of Fletcher and Peto demon-
strated that chronic bronchitis and respiratory infections
did not relate to lung function decline [3]. As a conse-
quence for many years it was believed that the chronic
bronchitis syndrome had no relevance to lung function
decline in COPD. However more recent studies have de-
scribed a relationship between lung function decline and
respiratory infections. Chronic bronchitis [4], respiratory
infections [5,6] and sputum bacterial counts [7]; have
been shown to be related to decline in lung function in
COPD. The role of chronic bronchitis remains contro-
versial though.* Correspondence: paul.king@monash.edu
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in any medium, provided the original work is pA relatively recently realized feature of COPD is in-
tense bronchial inflammation; that persists despite the
cessation of smoking and is most prominent in advanced
disease [8,9]. The factors that drive the inflammatory
process after smoking cessation have not been clearly
defined [10]. Bacterial infection is one potential candi-
date and bacteria can induce inflammation both in the
context of exacerbations and in the stable baseline state.
Antibiotics have been used as standard management
for the treatment of exacerbations of COPD, but their
value in this context remains uncertain [11]. Recent tri-
als of the long-term use of macrolides have shown
promising results [12].
This review will discuss the role of bacteria in the
pathogenesis of COPD. Methods of diagnosing respira-
tory infection will be reviewed and the potential effect of
antibiotics and other therapies in treatment.
Microbiology of the respiratory tract
Bacteria have established niches in the human body
where they exist in symbiosis with their host. The term
microbiome is used to refer to complex communities of
microorganisms, termed the microbiota, that inhabit the
body surfaces in symbiosis with the host [13]. The most
clearly defined microbiome occurs in the gastrointestinalOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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the whole human body (as bacteria are much smaller
than human cells). Bacteria which form part of the nor-
mal flora of the microbiome, are tolerated by the local
mucosal immune response with minimal activation of
inflammatory cells, in particular T cells [14]. Significant
recent advances in the understanding of the human
microbiome have been facilitated by the detection of the
highly conserved 16S ribosomal RNA present in bac-
teria. The 16S ribosome is present on bacterial (but not
human) cells [15]. Using 16S sequencing it has become
apparent that there are a vast number of different bac-
teria present in the normal human body.The upper re-
spiratory tract (especially the nasopharynx and the
mouth) is densely colonized by a large variety of bacteria
[16]. The colonization of this microbiome is a dynamic
process with frequent turnover of different strains. A
number of these bacteria are potentially pathogenic
micro-organisms (PPM) if they move into the lower re-
spiratory tract [17]. These potential pathogens may
colonize the upper airway for long periods such as
Haemophilus influenzae, Moxarella catarrhalis and
Streptococcus pneumoniae or for transient periods such as
Mycoplasma pneumoniae [18,19]. A recent study has de-
scribed that the depletion of the normal microbiome is as-
sociated with an increased prevalence of Corynebacterium
tuberculostearium that mediates rhinosinusitis; thisTable 1 Studies of the lung microbiome in COPD
Study Subjects (n) Sample Key findings
Hilty et al. 2010 [21] 8 Control BAL/Brush Pathogenic bacte
11 Asthma
5 COPD




Erb-Downward et al. 2011
[23]
9 Control/ BAL Core pulmonary
5 COPD
6 severe COPD







Pragmann et al. 2012 [25] 10 Control BAL Detectable bacte
22 COPD
Morris et al. 2013 [15] 32 Smoker Oral wash Mouth communi
30 Non-
smokerpathogen could potentially have a role in the lower re-
spiratory tract [20].
The lower respiratory tract is directly connected to the
upper respiratory tract with frequent micro-aspiration of
secretions. With the use of 16S sequencing it has been
recently recognized that the lower respiratory tract is in
fact not sterile but contains a variety of bacteria [16].
The bacteria present in the lower respiratory tract could
be quickly cleared by host defense, may persist as patho-
gens causing ongoing inflammation or form a lower re-
spiratory tract microbiome (i.e. bacteria exist in
symbiosis with the host). It has also become apparent
that patients with chronic airways disease (asthma and
COPD) have a different spectrum of bacteria in the
lower respiratory tract than those with normal lungs
[15,21-25]. These studies have generally found a close
correlation between the upper and lower airway
microbiome. It should be emphasized that defining the
lower airway bacteria is challenging and the studies done
so far have had small numbers. The quality of the data
varies and studies have used a range of techniques to
sample the lower airway. Recent studies of the lower re-
spiratory tract microbiome are listed in Table 1.
Several studies have demonstrated the presence of
bacteria particularly H. influenzae in surgical lung tissue
in patients with COPD [26,27]. The ability of bacteria to
invade into the respiratory tract and persist for longria, e.g. H. influenzae in asthma and COPD subjects
f pharynx have different microbial communities which are changed by
microbiota in BAL & lung tissue
terial communities in the same lung
rial communities in lung tissue that changes in severe COPD
ties different in smoker
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tially important [28].
The potential role of bacteria in COPD
COPD is characterized by airway inflammation that
causes progressive pulmonary damage. The primary risk
factor is smoking which has a variety of pathogenic ef-
fects on the airway. However it has been recognized that
airway inflammation persists after smoking cessation [8].
Hogg et al. have described the presence of lymphoid fol-
licles in the airway walls of ex-smokers that have a key
role in driving inflammation and airflow obstruction [9].
These lymphoid follicles are likely to be resulting from
the presence of persistent lung antigen but what this
could be has not been well defined. Potential antigens
include autoimmune antibodies, embedded heavy metals
from smoking and bacterial infection [29].
Smoking has a number of long-term effects on the
lung host defense that persist after smoking cessation
and increase the risk of secondary bacterial infection
[30]. These include permanent structural damage and
changes in the function of host immune cells including
macrophages, NK cells, dendritic cells and lymphocytes.
The ability of bacteria to cause disease is primarily re-
lated to overcoming the protective host immune re-
sponse. Both the structural airway integrity and cellular
immune response have a critical role. The airways se-
crete anti-microbial peptides such as defenses which
control microflora [31]. Rhinovirus infections can
downregulate the production of these peptides and this
may be important in exacerbations of COPD [32].
Presence of bacteria in exacerbations of COPD
A factor put forward for the relevance of bacteria in
COPD is their strong association with exacerbations.
Approximately 50% of exacerbations of COPD are asso-
ciated with the isolation of bacteria from the lower re-
spiratory tract [33,34]. The dominant bacterium are; H.
influenzae, S. pneumoniae and Moxarella catarrhalis. In
advanced disease P. aeruginosa becomes more prevalent
[34]. There are challenges in obtaining a representative
sample; but studies of sputum and bronchoscopy sam-
ples using standard culture and molecular techniques
have clearly demonstrated that COPD exacerbations are
associated with a markedly increased prevalence of
bacteria.
The bacteria that are associated with exacerbations
could potentially be new strains of bacteria from the
upper respiratory tract or from chronic colonization of
the lower respiratory tract. Sethi and colleagues have de-
scribed that the acquisition of a new strain of bacteria
(particularly H. influenzae) is associated with COPD ex-
acerbations [35,36]. However only a minority of exacer-
bations were associated with the acquisition of a newstrain. It has been difficult to define, but 38-73% of pa-
tients with stable COPD have been described to have the
presence of PPMs on baseline sputum [7,37-41], and on
bronchoscopy between 33-50% [42-44]. Exacerbations
could arise in the context of these resident bacteria.
Similar to the upper airway the lower airway bacterial
colonization is a dynamic process with turnover of
strains.
A recently described entity is bacterial and viral co-
infection. This may be present in up to 25% of exacerba-
tions and is associated with worse clinical outcomes and
more severe disease [37,45,46]. The viral infection may
down-regulate host defense leading to enhanced bacter-
ial proliferation and inflammation. Malia et al. have re-
cently demonstrated that experimental rhinovirus
infection is associated with a very high rate of bacterial
exacerbation in COPD patients [32].Bacteria and decline in lung function
There is indirect evidence correlating the decline in lung
function with airway infection and chronic bronchitis in
COPD [47,48]. Chronic bronchitis, respiratory infections
and sputum bacterial counts have been shown to be re-
lated to decline in lung function in COPD. The studies
that have been done in this regard have generally been
cross-sectional rather than longitudinal. The demonstra-
tion that the clearance of bacteria is associated with im-
proved lung function would be an important advance.Role of bacteria in inflammation
COPD is characterized by persistent inflammation that
damages lung tissue, causing airflow obstruction. This
inflammation persists after smoking. Neutrophils, mac-
rophages and T cells produce mediators such as cyto-
kines, reactive oxygen species and proteases to drive this
process [10,29,49]. Whilst it is generally accepted that
bacteria are very commonly found in the airways in
COPD, their role in the inflammatory process is less well
defined.In exacerbations of COPD
Two studies have reported increased levels of the in-
flammatory mediators, interleukin (IL) 8, tumor necrosis
factor alpha (TNF-α), neutrophils and elastase with bac-
teria [50,51]. Other studies have found that bacterial ex-
acerbations were associated with an increase in a variety
of parameters including neutrophils, eosinophils, TNF-α,
IL-1, CCL 5, CCL3 and CXCL11 [52-57]. Sethi et al.
found that the presence of H. influenzae and M.
catarrhalis was associated with increased sputum in-
flammatory markers [58].
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This may also contribute to chronic airway inflamma-
tion. White et al. showed that resolution of inflammation
after an exacerbation is dependent on bacterial clear-
ance; when this does not occur there may be ongoing in-
flammation [59]. Chronic airway colonization has been
shown to be related to the frequency and severity of ex-
acerbations [7,40,60] and sputum inflammatory markers
[41,60]. In stable patients airway colonization has been
demonstrated to have increased levels of airway inflam-
matory markers including TNF-α, IL-1, IL-6, IL-12,
matrix metalloproteinase (MMP), myeloperoxidase and
neutrophil elastase [38,41,42,60-62]. The load of bacteria
has been described to be related to the exacerbations
and inflammation; using both culture [7] and molecular
techniques [63] although other researchers have come to
different conclusions [36].
Lymphocyte are recognized to have a key role in driv-
ing inflammation in COPD but the antigens that activate
these cells have not been well defined. We have recently
demonstrated that nontypeable Haemophilus influenzae
(NTHi) strongly activates T cells obtained from surgical
lung tissue to cause a proinflammatory, profibrotic re-
sponse that also enhances airway reactivity [64]. This
work suggests that NTHi has a role in driving T cell me-
diated inflammation in COPD. Factors which suggest a
role for bacteria in the pathogenesis of COPD are sum-
marized in listed below.
Factors that imply a potential role for bacteria in
COPD
1. Present in approximately 50% of lower airway
samples in exacerbations
2. Colonize the airways in approximately 33-73% of
COPD patients
3. Chronic bronchitis, respiratory infections and
sputum bacterial counts are associated with lung
function decline
4. Bacteria are associated with increased inflammatory
markers in exacerbations
5. Chronic airway colonization is related to the
frequency and severity of exacerbations and to levels
of airway inflammatory markers
6. Bacteria activate lung T cells in COPD to produce a
pro-inflammatory response
Diagnosis of bacteria and infection
The available literature suggests that bacteria are an im-
portant cause of inflammation in COPD however this is
probably only in a proportion of patients. COPD is a
heterogeneous condition and recent efforts have been
made to phenotype this condition. Patients with chronic
bronchitis and with frequent exacerbations could repre-
sent a phenotype associated with bacterial infection[47,65]. The evidence that the identification of specific
bacteria changes treatment outcomes is minimal. How-
ever this may change with better quality studies and
newer techniques.
Sputum samples are the first-line investigation used.
Stockley et al. have established that the production of
purulent sputum that is graded on a color scale (from
white to dark green; as a marker of neutrophils) is
strongly associated with bacterial infection [66,67]. A
good quality specimen that is representative of the lower
airway should have; < 10 squamous epithelial cells
and >25 polymorphs in low power field [68,69]. Sputum
culture results have the highest validity when they are
consistent with the gram stain (e.g. G-ve bacilli on gram
stain accompanied by growth of P. aeruginosa on cul-
ture) [70,71]. The use of nucleic acid amplification tests
(NAAT) may increase the yield of fastidious pathogens
such as M. pneumoniae and C. pneumoniae [72,73].
The diagnostic yield may be increased by the use of
bronchoscopy. There is a significant issue of potential
contamination as the bronchoscope is initially passed
through the upper airway. The protected specimen
brush is more specific than the bronchoalveolar lavage
(BAL) although it does have the issue of only obtaining
small specimen amounts [74]. Using a cut off of colony
forming units (CFU) of bacteria per ml of specimen (e.g.
103 ml) increases sensitivity [75,76]. As described previ-
ously 16S sequencing has given a new perspective on the
lower airway; at this stage it is primarily a research tool
but in time is likely to become more mainstream.
There may also be significant merit in taking bronchial
biopsies or examining surgical lung specimens for the
presence of bacteria as this tissue should be sterile. Patel
et al. described the presence of intracellular H.
influenzae in 14/15 patients having an exacerbation of
COPD (and none in controls) [40]. Moller et al. exam-
ined the explants of patients with COPD (and other con-
ditions) and found widespread invasion of lung tissue
with intracellular H. influenzae in half of the subjects
[77]. More recently, Droman et al. described the pres-
ence of this bacterium in the lung tissue in 40% of pa-
tients in all stages of COPD [27].
Use of antibiotics in COPD
There is a lack of good quality trials concerning the ef-
fectiveness of antibiotics for the treatment of COPD and
this more than anything has contributed to the contro-
versy about the role of bacteria in the pathogenesis of
this condition.
Use of antibiotics for exacerbations of COPD
There have been a number of problems with the anti-
biotic trials in COPD exacerbations; particularly with is-
sues of lack of placebo control, poorly defined patient
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sured [78,79]. In many trials it has been felt that it is not
ethical to withhold antibiotics (i.e. use a placebo) so typ-
ically designs have compared one antibiotic with another
[78,80].
Perhaps the best study to date is that of Anthonisen
et al. who used a randomized, double-blind design [81].
They defined three cardinal symptoms of increasing; 1)
dyspnea 2), sputum volume and 3) sputum purulence.
Subjects who had two symptoms (type 2) or three symp-
toms (type 1) had a modest benefit from antibiotics
(subjects with one symptom had no benefit).
A recent Cochrane review assessed the use of antibi-
otics for exacerbations of COPD [11]. Sixteen random-
ized controlled trials of 2068 subjects were included. In
mild exacerbations they found there was evidence of low
quality that antibiotics significantly reduced the risk of
treatment failure 7 days to one month after treatment
initiation. Evidence of high quality demonstrated a sig-
nificant reduction in treatment failure in in-patients with
severe exacerbations. Evidence of moderate quality dem-
onstrated an increased risk of side effects with antibi-
otics (particularly diarrhea).
A recent trial by Llor et al. evaluated the effect of anti-
biotics in an ambulatory population of mild-moderate
exacerbations [82]. This trial randomized patients to be
either treated with amoxicillin/clavulanate (n=117) or
placebo (n=91). They found that the use of antibiotics
was more effective and significantly prolonged the time
to next exacerbation when compared to placebo. This is
the first trial to show a clear benefit in the outpatient
setting and one of the few trials that has used a placebo.
Other criteria have been proposed as being useful in
determining whether antibiotics are indicated for exacer-
bations. Sputum purulence is correlated with bacterial
infection [67] and withholding antibiotics in those with-
out purulent sputum may be safe [67,83]. Procalcitonin
is a marker of bacterial infection and may be a useful
guide as to whether antibiotics are indicated [84,85].
The most commonly used biomarker in COPD is the C-
reactive protein (CRP). Llor et al. found that a CRP of >
40 mg/L in the placebo group predicted clinical failure
[82]. The role of biomarkers as a marker of inflamma-
tion in COPD is an area of active research with several
recent large studies published. MacNee has recently
reviewed this topic [86] and has highlighted the role of
the lung-specific factors CCL-18/PARC and SP-D, which
are closely correlated with clinical outcomes (e.g. exacer-
bations) and anti-inflammatory therapy; fibrinogen
whilst less organ specific may also be helpful.
Use of antibiotics in stable COPD
There is increasing evidence that bacteria contributes to
lung inflammation both in exacerbations and in stableCOPD. Antibiotics have used for the treatment of
chronic bronchitis for many years with trials first done
50 years. Staykova et al. reviewed the early trials and
found a small reduction in days of illness in exacerba-
tions [87]. Due to lack of good data and concerns about
antibiotic resistance this approach was rarely used for
the management of stable COPD. However this has
changed recently with a series of trials that have used
macrolides.
Seemungal et al. assessed a cohort of 109 patients ran-
domized to treatment with erythromycin or placebo for
a year and found there was a significant reduction in ex-
acerbations in the erythromycin group [88]. A major
study of 1142 subjects who were randomized to treat-
ment with azithromycin 250mg daily or placebo for a
year found a significant reduction in exacerbations and
improvement in quality of life in the treatment arm [12].
Several other studies have found that macrolides reduce
exacerbations of COPD [89-91]. The mechanisms by
which macrolides reduce exacerbations are unknown.
There is significant overlap with bronchiectasis and
COPD. Two trials have reported in COPD a prevalence
of bronchiectasis of 29% and 50% [92,93]. Two studies
have found improved outcomes in cohorts of bronchiec-
tasis patients treated with macrolides. Wong et al. dem-
onstrated that the use of azithromycin at 500mg three
times a week significantly reduced exacerbations when
compared to control [94]. Similarly Serisier et al. found
that the use of erythromycin 400mg twice daily for 12
months reduced exacerbations when compared to con-
trol [95].
There are some potential problems with the use of
macrolides to prevent exacerbations [96]. Azithromycin
has a mildly increased risk of hearing deficits and
prolonged QT syndrome with a one study reported a
slightly increased risk of cardiac death [97]. However a
more recent study found no increased risk of cardiac
death [98]. Macrolides should probably be given with
caution to subjects with significant cardiac or vascular
disease. There are drug interactions especially with
statins, warfarin and amiodarone. There is also an in-
creased risk of antibiotic resistance including to S.
pneumoniae and Mycobacterium avium complex. Wen-
zel et al. recommend that macrolides (azithromycin)
should be considered as maintenance therapy in subjects
who have at least 2 exacerbations in past year despite
optimal therapy and no significant contraindications
[96].
Other therapies to treat infection in COPD
Antibiotics are a limited resource and should be used
when there is a strong clinical indication. There is a sig-
nificant need for other therapeutic modalities to treat in-
fection in the context of COPD.
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The influenza and pneumococcal vaccines are a fre-
quent part of standard management of COPD [99].
Viral influenza is associated with increased exacerba-
tions of COPD and a higher risk of hospitalization. A
Cochrane review in 2006 found that vaccination
resulted in a mildly decreased risk of exacerbations. The
vaccine may be given as inactive or attenuated forms
and both forms appear safe with no clear differences in
efficacy [100].
Streptococcus pneumoniae is a major cause of acute
exacerbations of COPD and may also colonize the lower
airway. The vaccine has two forms, the valent polysac-
charide vaccine and the newer conjugated vaccine. The
conjugated vacccine induces a stronger immune re-
sponse and may potentially be more effective. Three
retrospective studies demonstrated a reduction in the in-
cidence of pneumonia, hospitalizations and invasive dis-
ease [101-103]. A Cochrane review found a reduction in
invasive pulmonary disease after pneumococcal vaccin-
ation but no reduction in all-cause pneumonia or mor-
tality [104].
In addition to influenza and pneumococcal vaccination
the Centers for Disease Control (CDC) and American
Society for Infectious Diseases (ASID) also recommend
Pertussis and Herpes Zoster vaccination in patients with
COPD. The evidence supporting the use of Pertussis and
Herpes Zoster vaccination in this context is minimal.
The nontypeable form of Haemophilus influenzae is
the dominant bacterium in patients with COPD and
there have been studies of the use of vaccination against
this pathogen intermittently for a number of years. An
inactivated vaccine has been previously shown to reduce
the incidence of acute exacerbations in COPD but was
not widely used [105]. A more recent study has again
demonstrated that oral vaccination is safe and reduces
severe exacerbations [106]. A successful vaccine against
H. influenzae would be a major advance in management.Use of corticosteroids
Systemic corticosteroids are standard therapy for the
treatment of COPD exacerbations. The combination of
corticosteroids and antibiotics for exacerbations has
been demonstrated to improve outcomes when com-
pared to either agent alone [107].
The long-term use of corticosteroids on infection in
COPD is not clear-cut. Corticosteroids are potentially
beneficial by reducing inflammation, however this results
in a down-regulation of host defense and increased risk
of infection. Maintenance therapy with inhalational cor-
ticosteroids has been shown to reduce the number of ex-
acerbations but conversely increase the rate of
pneumonia [108].Other agents
As the viral-bacterial co-infection is associated with
worse outcomes in COPD there may be a role for antivi-
rals in the treatment of exacerbations. Neuraminidase-
inhibitors for the treatment of influenza may be benefi-
cial although there appears to be no clear literature to
guide this choice. Recently drugs have been developed
against the rhinovirus including the capsid-binding
agent, pleconaril [109].
As bacterial infection produces inflammation, the use
of anti-inflammatory agents may be useful. Phospho-
diesterase inhibitors such as roflumilast and cilomilast
reduce inflammation and exacerbations in COPD
[110,111]. Antioxidants such as N-acetylcysteine in sub-
group analysis may reduce exacerbations [112]. Whether
these effects are relevant to bacterial infection remains
to be determined.
The intestinal microbiome has recently been recog-
nized to have general effects on host immunity including
in the lung. Therefore the use of probiotics to enhance
normal intestinal flora may have potentially beneficial ef-
fects on lung inflammation. Forsythe has reviewed this
topic; whilst animal data has shown promising results
for the use of probiotics to reduce lung inflammation,
human studies have so far been inconclusive [113].Conclusions
Increasing evidence has demonstrated that bacteria are
very common in the lower respiratory tract of patients
with COPD and cause inflammation. Antibiotics have a
clear role in the treatment of a proportion of subjects.
There are still very large gaps in understanding how bac-
teria contribute to inflammation in COPD and what are
the best methods to diagnose their presence in individ-
ual patients. Antibiotics are a limited resource and
establishing how they should best be utilized to treat in-
fection in COPD will be a major challenge. The develop-
ment of alternative therapies is likely to be critical to
long-term improvement in management.Competing interests
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